

## 6. Literatur

1. Abbas J, Bodey GP, Hanna HA et al.  
Candida krusei fungemia. An escalating serious infection in immunocompromised patients.  
Arch Intern Med 2000; 160: 2659-2664.
2. Akpan A, Morgan R.  
Oral candidiasis.  
Postgrad Med J 2002; 78: 455-459.
3. Arendorf TM, Bredekamp B, Cloete C et al.  
Oral manifestations of HIV infection in 600 South African patients.  
J Oral Pathol Med 1998; 27: 176-179.
4. Armitage GC.  
Development of a classification system for periodontal diseases and conditions.  
Ann Periodontol 1999; 4: 1-6.
5. Ashman RB, Papadimitriou JM.  
Production and function of cytokines in natural and acquired immunity to Candida albicans infection.  
Microbiol Rev 1995; 59: 646-672.
6. Axelsson P.  
A four-point scale for selection of caries patients, based on salivary S. mutans levels and plaque formation rate index.  
In: Johnson NW, ed. Risk Markers for Oral Diseases. Caries.  
Cambridge University Press, Cambridge, 1991, pp 159-171
7. Bascones-Martinez A., Figuero-Ruiz E. (2004)  
Periodontal diseases as bacterial infection.  
Med Oral Patol Oral Cir Bucal 101-107, 92-100
8. Begg MD, Panageas KS, Mitchell-Lewis D et al.  
Oral lesions as markers of severe immunosuppression in HIVinfected homosexual men and injection drug users.  
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996; 82: 276-283.
9. Begg MD, Lamster IB, Panageas KS et al.  
A prospective study of oral lesions and their predictive value for progression of HIV disease.  
Oral Dis 1997; 3: 176-183.

10. Bergbrant IM, Faergemann J.  
Quantitative cultures of *Candida* from mouthwash fluid in HIV-infected patients: a longitudinal study.  
*Mycoses* 1997; 40: 377-380.
11. Blot S, Janssens R, Claeys G et al.  
Effect of fluconazole consumption on long-term trends in candidal ecology.  
*J Antimicrob Chemother* 2006; 58: 474-477.
12. Büchner T, Fegeler W, Bernhardt H et al.  
Treatment of severe candida infections in high-risk-patients in Germany: Consensus formed by a panel of interdisciplinary investigators.  
*Eur J Clin Microbiol Infect Dis* 2002; 21: 337-352.
13. CDC Centers for Disease Control and Prevention:  
1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults.  
<http://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm> (Zugriff: 18.03.2006).
14. Ceballos-Salobrena A, Aguirre-Urizar JM, Bagan-Sebastian JV.  
Oral manifestations associated with human immunodeficiency virus infection in a Spanish population.  
*J Oral Pathol Med* 1996; 25: 523-526.
15. Charlier C, Hart E, Lefort A et al.  
Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?  
*J Antimicrob Chemother* 2006; 57: 384-410.
16. Coleman DC, Rinaldi MG, Haynes KA et al.  
Importance of *Candida*-species other than *Candida albicans* as opportunistic pathogens.  
*Med Mycol* 1998; 36: 156-165.
17. Colombo AL, Perfect J, DiNubile M et al.  
Global distribution and outcomes for *Candida*-species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis.  
*Eur J Clin Microbiol Infect Dis* 2003; 22: 470-474.
18. EC-Clearinghouse on Oral Problems Related to HIV Infection and WHO Collaborating Centre on Oral Manifestations of the Immunodeficiency Virus.  
Classification and diagnostic criteria for oral lesions in HIV infection.  
*J Oral Pathol Med* 1993; 22: 289-291.

19. Felix DH, Wray D.  
The prevalence of oral candidiasis in HIV-infected individuals and dental attenders in Edinburgh.  
J Oral Pathol Med 1993; 22: 418-420.
20. Fortún J, López-San Román A, Velasco JJ et al.  
Selection of *Candida glabrata* strains with reduced susceptibility to azoles in four liver transplant patients with invasive candidiasis.  
Eur J Clin Microbiol Infect Dis 1997; 16: 314-318.
21. Friedman RB, Gunsolley J, Gentry A, Dinius A, Kaplowitz L, Settle J.  
Periodontal status of HIV-seropositive and AIDS patients.  
J Periodontol 1991; 62: 623-627.
22. Garber G.  
An overview of fungal infections.  
Drugs 2001; 61: 1-12.
23. Gillespie G, Mariño R.  
Oral manifestations of HIV infection: a Panamerican perspective.  
J Oral Pathol Med 1993; 22: 2-7.
24. Glick M, Pliskin ME, Weiss RC.  
The clinical and histologic appearance of HIV-associated gingivitis.  
Oral Surg Oral Med Oral Pathol 1990; 69: 395-398.
25. Gomez RS, da Costa JE, Loyola AM, de Araujo NS, de Araujo VC.  
Immunohistochemical study of linear gingival erythema from HIV-seropositive patients.  
J Periodontal Res 1995; 30: 355-359.
26. Grbic JT, Mitchell-Lewis DA, Fine JB et al.  
The relationship of candidiasis to linear gingival erythema in HIV-infected homosexual men and parenteral drug users.  
J Periodontol 1995; 66: 30-37.
27. Greenspan JS, Barr CE, Sciubba JJ, Winkler JR.  
Oral manifestations of HIV infection. Definitions, diagnostic criteria, and principles of therapy. The U.S.A. Oral AIDS Collaborative Group.  
Oral Surg Oral Med Oral Pathol 1992; 73: 142-144.

28. Hämmerle C, Grassi M, Winkler JR.  
HIV-Parodontopathien. Diagnostik und Therapie der HIV-assoziierten Gingivitis/Parodontitis.  
Schweiz Monatsschr Zahnmed 1992; 102: 940-950.
29. Hauman CH, Thompson IO, Theunissen F, Wolfaardt P.  
Oral carriage of Candida in healthy and HIV-seropositive persons.  
Oral Surg Oral Med Oral Pathol 1993; 76: 570-572.
30. Holmstrupp P.  
Non-plaque-induced gingival lesions.  
Ann Periodontol 1999; 4: 20-29.
31. Holmstrup P, Westergaard J.  
HIV infection and periodontal diseases.  
Periodontol 2000 1998; 18: 37-46.
32. Klein RS, Quart AM, Small CB.  
Periodontal disease in heterosexuals with acquired immunodeficiency syndrome.  
J Periodontol 1991; 62: 535-540.
33. Komshian SV, Uwaydah AK, Sobel JD, Crane LR.  
Fungemia caused by Candida-species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome.  
Rev Infect Dis 1989; 11: 379-390.
34. Kroidl A, Schaeben A, Oette M et al.  
Prevalence of oral lesions and periodontal diseases in HIV-infected patients on antiretroviral therapy.  
Eur J Med Res 2005;10: 448-453.
35. Kullberg BJ, Oude Lashof AM.  
Epidemiology of opportunistic invasive mycoses.  
Eur J Med Res 2002; 7: 183-191.
36. Lamster IB, Begg MD, Mitchell-Lewis D et al.  
Oral manifestations of HIV infection in homosexual men and intravenous drug users. Study design and relationship of epidemiologic, clinical, and immunologic parameters to oral lesions.  
Oral Surg Oral Med Oral Pathol 1994; 78: 163-174.
37. Lamster IB, Grbic JT, Bucklan RS et al.  
Epidemiology and diagnosis of HIV-associated periodontal diseases.  
Oral Dis 1997; 3 Suppl 1: S141-148.

38. Lamster IB, Grbic JT, Mitchell-Lewis DA, Begg MD, Mitchell A.  
New concepts regarding the pathogenesis of periodontal disease in HIV infection.  
Ann Periodontol 1998; 3: 62-75.
39. Lange DE, Plagmann HC, Eenboom A, Promesberger A.  
Klinische Bewertungsverfahren zur Objektivierung der Mundhygiene.  
Dtsch Zahnärztl Z 1977; 32: 44-47.
40. Little JW, Melnick SL, Rhame FS et al.  
Prevalence of oral lesions in symptomatic and asymptomatic HIV patients.  
General Dent 1994; 42: 446-450.
41. Martin GS, Mannino DM, Eaton S, Moss M.  
The epidemiology of sepsis in the United States from 1979 through 2000.  
N Engl J Med 2003; 348: 1546-1554.
42. Maschmeyer G, Ruhnke M.  
Update on antifungal treatment of invasive Candida and Aspergillus infections.  
Mycoses 2004; 47: 263-276.
43. Masia CM, Gutiérrez RF.  
Antifungal drug resistance to azoles and polyenes.  
Lancet Infect Dis 2002; 2: 550-563.
44. Masouredis CM, Katz MH, Greenspan D, Herrera C, Hollander H, Greenspan JS, Winkler JR.  
Prevalence of HIV-associated periodontitis and gingivitis in HIV-infected patients attending an AIDS clinic.  
J Acquir Immune Defic Syndr 1992; 5: 479-483.
45. Matuschak GM, Lechner AJ.  
The yeast to hyphal transition following hematogenous candidiasis induces shock and organ injury independent of circulating tumor necrosis factor-alpha.  
Crit Care Med 1997; 25: 111-120.
46. Metzger S, Hofmann H.  
Fluconazol-resistente Candida-Arten bei HIV-Patienten mit rezidivierenden Candida-Stomatitiden: Kreuzresistenz zu Itraconazol und Ketoconazol.  
Mycoses 1997; 40 (Suppl 1): 56-63.

47. Merck.  
Reisextrakt-Agar.  
Version 21-01-2003, Merck KGaA, 64271 Darmstadt, Germany.  
<http://www.merck.de/servlet/PB/show/1127170/bz110424d.pdf> (Zugriff:  
18.03.2006).
48. Miyazaki H, Miyazaki Y, Geber A et al.  
Fluconazole resistance associated with drug efflux und increased transcription of a  
drug transporter gene, PDH1, in *Candida glabrata*.  
*Antimicrob Agents Chemother* 1998; 42: 1695-1701.
49. Murray PA, Grassi M, Winkler JR.  
The microbiology of HIV-associated periodontal lesions.  
*J Clin Periodontol.* 1989; 16: 636-642.
50. Nittayananta W, Chanowanna N, Sripatanakul S, Winn T.  
Risk factors associated with oral lesions in HIV-infected heterosexual people and  
intravenous drug users in Thailand.  
*J Oral Pathol Med* 2001; 30: 224-230.
51. Nucci M, Colombo AL.  
Emergence of resistant *Candida* in neutropenic patients.  
*Braz J Infect Dis* 2002; 6: 124-128.
52. Odds FC.  
*Candida* infections: an overview.  
*Crit Rev Microbiol* 1987; 15: 1-5.
53. Odds FC.  
Pathogenesis of *Candida* infections.  
*J Am Acad Dermatol* 1994; 31: S2-S5
54. Patton LL, McKaig RG, Strauss RP, Eron JJ Jr.  
Oral manifestations of HIV in a southeast USA population.  
*Oral Dis* 1998; 4: 164-169.
55. Patton LL, van der Horst C.  
Oral infections and other manifestations of HIV disease.  
*Infect Dis Clin North Am* 1999; 13: 879-900.
56. Patton LL.  
Sensitivity, specificity, and positive predictive value of oral opportunistic infections  
in adults with HIV/AIDS as markers of immune suppression and viral burden.  
*Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2000; 90: 182-188.

57. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP.  
National surveillance of nosocomial blood stream infection due to species of *Candida* other than *Candida albicans*: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic.  
Diagn Microbiol Infect Dis 1998; 30: 121-129.
58. Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC, Hollis RJ, Messer SA and the SENTRY Participant Group.  
International surveillance of bloodstream infections due to *Candida* species: Frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program.  
J Clin Microbiol 2001; 39: 3254-3259.
59. Piluso S, Ficarra G, Orsi A, Gaglioti D, Pierotti P, Orlando S.  
Clinical aspects and microbiology of HIV-associated periodontal lesions.  
Minerva Stomatol. 1993; 42: 301-309.
60. Pistorius A, Willershausen B.  
Cases of HIV-associated characteristic periodontal diseases.  
Eur J Med Res 1999; 4: 121-125.
61. Porter SR, Luker J, Scully C, Glover S, Griffiths MJ.  
Orofacial manifestations of a group of British patients infected with HIV-1.  
J Oral Pathol Med 1989; 18: 47-48.
62. Quart A, Reich D.  
Fungi in the gingival sulcus – frequency and speciation in HIV+ and HIV-heterosexual patients.  
Periodontal Clin Investig 1995; 17: 10-12.
63. Quigley GA, Hein JW.  
Comparative cleansing efficiency of manual and power brushing.  
JADA 1962; 65: 26-29
64. Ramírez-Amador V, González M, De la Rosa E, Esquivel L, Volkow P Ochoa FJ, Meneses A, Mohar A.  
Oral findings in Mexican AIDS patients with cancer.  
J Oral Pathol Med 1993; 22: 87-91.

65. Ramírez-Amador V, Esquivel-Pedraza L et al.  
The changing clinical spectrum of human immunodeficiency virus (HIV)-related oral lesions in 1,000 consecutive patients. A twelve-year study in a referral center in Mexico.  
Medicine 2003; 82: 39-50.
66. Ranganathan K, Reddy BV, Kumarasamy N, Solomon S, Viswanathan R, Johnson NW.  
Oral lesions and conditions associated with human immunodeficiency virus infection in 300 south Indian patients.  
Oral Dis 2000; 6: 152-157.
67. Redding SW, Kirkpatrick WR, Dib O, Fothergill AW, Rinaldi MG, Patterson TF.  
The epidemiology of non-albicans Candida in oropharyngeal candidiasis in HIV patients.  
Special Care Dent 2000; 20: 178-181.
68. Renggli HR.  
Äthiologie marginaler Parodontopathien.  
In Ketterl W (Hrsg): Praxis der Zahnheilkunde 4 – Parodontologie (2. Auflage).  
Urban & Schwarzenberg, München, Wien, Baltimore 1990, S. 33-64
69. Rennert G, Rennert HS, Pitlik S, Finkelstein R, Kitzes-Cohen R.  
Epidemiology of candidemia – a nationwide survey in Israel.  
Infection 2000; 28: 26-29.
70. Rex JH, Walsh TJ, Anaissie EJ.  
Fungal infection in iatrogenically compromised hosts.  
Adv Int Med 1998; 43: 321-371.
71. Reznik DA.  
Oral manifestations of HIV disease.  
Top HIV Med 2005/2006; 13: 143-148.
72. Richardson MD.  
Changing patterns and trends in systemic fungal infections.  
J Antimicrob Chemother. 2005;56 (Suppl 1): i5-i11.
73. Riley C, London JP, Burmeister JA.  
Periodontal health in 200 HIV-seropositive patients.  
J Oral Pathol Med. 1992; 21: 124-127.



74. Roberts GD.  
Laboratory diagnosis of fungal infections.  
Hum Pathol 1976; 7: 161-168.
75. Robinson PG, Sheiham A, Challacombe SJ, Zakrzewska JM.  
The periodontal health of homosexual men with HIV infection: a controlled study.  
Oral Dis 1996; 2: 45-52.
76. Robinson PG.  
Treatment of HIV-associated periodontal diseases.  
Oral Dis 1997; 3 (Suppl 1): S238-S240.
77. Robinson PG.  
Which periodontal changes are associated with HIV infection?  
J Clin Periodontol 1998; 25: 278-285.
78. Robinson PG.  
The significance and management of periodontal lesions in HIV infection.  
Oral diseases 2002; 8 (Suppl 2): 91-97.
79. Robinson PG, Adegboye A, Rowland RW, Yeung S, Johnson NW.  
Periodontal diseases and HIV infection.  
Oral Dis 2002; 8 (Suppl 2): 144-150.
80. Samaranayake YH, Samaranayake LP.  
Candida krusei: biology, epidemiology, pathogenicity and clinical manifestations of an emerging pathogen.  
J Med Microbiol 1994; 41: 295-310.
81. Sanglard D, Ischer F, Calabrese D, Majcherczyk PA, Bille J.  
The ATP binding cassette transporter gene CgCDR1 von Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents.  
Antimicrob Agents Chemother 1999; 43: 2753-2765.
82. Schmidt-Westhausen A, Schiller RA, Pohle HD, Reichart PA.  
Oral Candida and Enterobacteriaceae in HIV-1 infection: correlation with clinical candidiasis and antimycotic therapy.  
J Oral Pathol Med 1991; 20: 469-472.
83. Schmidt-Westhausen AM, Pripke F, Bergmann FJ, Reichart PA.  
Decline in the rate of oral opportunistic infections following introduction of highly active antiretroviral therapy.  
J Oral Pathol Med 2000; 29: 336-341.

84. Schmidt-Westhausen AM; Bendick C; Reichart PA; Samaranayake LP.  
Oral candidosis and associated *Candida*-species in HIV-infected Cambodians exposed to antimycotics.  
*Mycoses* 2004; 47: 435-441.
85. Schoen DH, Murray PA, Nelson E, Catalanotto FA, Katz RV, Fine DH.  
A comparison of periodontal disease in HIV-infected children and household peers: a two year report.  
*Pediatr Dent* 2000; 22: 365-369.
86. Schoofs AG, Odds FC, Colebunders R, Ieven M, Goossens H.  
Cross-sectional study of oral *Candida* carriage in a human immunodeficiency virus (HIV)-seropositive population: predisposing factors, epidemiology and antifungal susceptibility.  
*Mycoses* 1998; 41: 203-211.
87. Schuman P, Ohmit SE, Sobel JD, Mayer KH, Greene V, Rimpalo A, Klein RS.  
Oral lesions among women living with or at risk for HIV infection.  
*Am J Med* 1998; 104: 559-564.
88. Sharma G, Pai KM, Suhas S, Ramapuram JT, Doshi D, Anup N  
Oral manifestations in HIV/AIDS infected patients from India.  
*Oral Dis* 2006; 12: 537-542.
89. Silness J, Løe H.  
Periodontal disease in pregnancy. II. Correlation between oral hygiene and periodontal condition.  
*Acta Odontol Scand* 1964; 22: 121-135.
90. Sobel JD, Ohmit SE, Schuman P, Klein RS, Mayer K, Duerr A, Vazquez JA, Rimpalo A, HIV Epidemiology Research Study (HERS) Group.  
The evolution of *Candida*-species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women.  
*J Infect Dis* 2000; 183: 286-293.
91. Sullivan D, Coleman D.  
*Candida dubliniensis*: characteristics and identification.  
*J Clin Microbiol* 1998; 36: 329-334.

92. Tortorano AM, Peman J, Bernhardt H, Klingspor L, Kibbler CC, Faure O, Biraghi E, Canton E, Zimmermann K, Seaton S, Grillot R, the ECMM Working Group on Candidaemia.  
Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study.  
Eur J Clin Microbiol Infect Dis 2004; 23: 317-322.
93. Tufano R.  
Focus on risk factors for fungal infections in ICU patients.  
Minerva Anesthesiol 2002; 68: 269-272.
94. van der Waal I.  
Some unusual oral lesions in HIV infection: comments on the current classification.  
Oral Dis 1997; 3 (Suppl 1): S197-S199.
95. Velasco E, Santos Thuler LC, de Souza Martins CA, Nucci M, Castro Dias LM, da Silva Castro Gonçalves VM.  
Epidemiology of bloodstream infections at a cancer center.  
Sao Paulo Med J 2000; 118: 131-138.
96. Velegraki A, Nicolatou O, Theodoridou M, Mostrou G, Legakis NJ.  
Paediatric AIDS--related linear gingival erythema: a form of erythematous candidiasis?  
J Oral Pathol Med 1999; 28: 178-182.
97. Viscoli C, Girmenia C, Marinus A et al.  
Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC).  
Clin Infect Dis 1999; 28: 1071-1079.
98. Warnock, D W, Burke, J, Cope, N J, Johnson, E M, von Fraunhofer, N A Williams, EW Fluconazole resistance in *Candida glabrata*. Lancet 1988; 8623 (2): 1310
99. Wenzel RP.  
Nosocomial candidemia: Risk factors and attributable mortality.  
Clin Infect Dis 1995; 20: 1531-1534.
100. Winkler JR, Robertson PB.  
Periodontal disease associated with HIV infection.  
Oral Surg Oral Med Oral Pathol 1992; 73: 145-150.

101. Yeung SC.  
HIV infection and periodontal disease.  
Ann R Australas Coll Dent Surg 2000; 15: 331-334.
102. Zafiropoulos GG, Stelzel M, Mengel R, Flores-de-Jacoby L, Kolb G.  
Die Sulkusflüssigkeit in der parodontalen Diagnostik. Eine Übersicht.  
Schweiz Monatsschr Zahnmed 1991; 101: 973-985.
103. Zink S, Naß T, Rösen P, Ernst JF.  
Migration of the fungal pathogen *Candida albicans* across endothelial monolayers.  
Infect Immun 1996; 64: 5085-5091.